Company Snapshot

Gene therapy and gene vaccines are mega-trends in personalised medicine which face significant constraints in capacity, cost, quality, safety and universal application.

Our aim is to address many of the limitations preventing gene based therapies becoming widely available.

4bb’s strategy is twofold:

  • First: DNA as the therapeutic agent is essential in every gene therapy or vaccine; 4bb’s proprietary enzymatic technology enables the manufacture and sale of large volumes of high quality optimised synthetic DNA (oDNA), thereby resolving several capacity, cost, quality and safety constraints.
  • Second: 4bb will invest in assets within the DNA and wider gene therapy work flow which are complementary to its core technology and which further address known constraints.